Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage precision oncology company, announced the closing of its registered direct offering, raising approximately $4.4 million in gross proceeds. The company sold 2,135,923 shares of common stock or pre-funded warrants at $2.06 per share. In a concurrent private placement, Lantern issued unregistered warrants to purchase up to an additional 2,135,923 shares at $2.27 per share, which could yield up to $4.85 million in additional proceeds if fully exercised. The full press release is available at https://ibn.fm/Oh6jI.
This capital infusion comes at a critical time for Lantern Pharma, which leverages artificial intelligence and machine learning through its proprietary RADR platform to transform cancer therapy development. The company is advancing a clinical pipeline that includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), currently being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The company also recently commercialized withZeta.ai, a multi-agentic AI co-scientist platform, now available as a subscription-based research platform for the global biomedical and drug development community. This new revenue stream positions Lantern to generate recurring income while expanding its AI capabilities. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The offering’s closure strengthens Lantern’s balance sheet, enabling continued investment in its precision oncology pipeline and AI platform. The potential additional $4.85 million from warrant exercises, if realized, would further extend the company’s runway for clinical trials and technology development. For the biotechnology industry, this funding round underscores growing investor confidence in AI-driven drug discovery and development, a sector that promises to reduce costs and accelerate timelines for bringing new cancer therapies to patients.
Lantern Pharma’s ability to raise capital through a registered direct offering, coupled with the strategic issuance of warrants, reflects a pragmatic approach to financing in a challenging market for clinical-stage biotechs. The company’s focus on using AI to identify patient populations most likely to benefit from its therapies could improve clinical trial success rates and deliver more targeted treatments. As Lantern advances its pipeline, the additional capital may support key milestones, including data readouts from the HARMONIC trial and expansion of LP-184 into pediatric CNS indications.
For investors and industry observers, this development highlights the increasing importance of AI in oncology and the potential for platforms like RADR to reshape drug development. Lantern’s dual strategy of advancing internal programs and commercializing its AI tools could create multiple value drivers, making the company one to watch in the precision oncology space.
